Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors

JAMA Oncology

Volumn 2, Issue 5, 2016, Pages 616-624

  Parsons, D Williams ^a   Roy, Angshumoy ^a,b   Yang, Yaping ^a   Wang, Tao ^a   Scollon, Sarah ^a   Bergstrom, Katie ^a   Kerstein, Robin A ^a   Gutierrez, Stephanie ^a   Petersen, Andrea K ^a   Bavle, Abhishek ^a   Lin, Frank Y ^a   López Terrada, Dolores H ^a,b   Monzon, Federico A ^a,b   Hicks, M John ^a,b   Eldin, Karen W ^a,b   Quintanilla, Norma M ^a,b   Adesina, Adekunle M ^a,b   Mohila, Carrie A ^a,b   Whitehead, William ^a,b   Jea, Andrew ^a,b   Vasudevan, Sanjeev A ^a,b   Nuchtern, Jed G ^a,b   Ramamurthy, Uma ^a   McGuire, Amy L ^a   Hilsenbeck, Susan G ^a   Reid, Jeffrey G ^a   Muzny, Donna M ^a   Wheeler, David A ^a   Berg, Stacey L ^a   Chintagumpala, Murali M ^a   Eng, Christine M ^a   Gibbs, Richard A ^a   Plon, Sharon E ^a   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Texas Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85010703579     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.5699     Document Type: Article

References (33)

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
2. Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med. 2013;369(16): 1502-1511.
3. Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312(18): 1870-1879.
4. Dorschner MO, Amendola LM, Turner EH, et al; National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project. Actionable, pathogenic incidental findings in 1, 000 participants' exomes. Am J Hum Genet. 2013;93(4): 631-640.
5. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013;31(15):1806-1814.
6. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21(12):2397-2406.
7. Scollon S, Bergstrom K, Kerstein RA, et al. Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients. Genome Med. 2014;6 (9):69.
8. Perry JA, Kiezun A, Tonzi P, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014;111(51): E5564-E5573.
9. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801-1811.
10. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.
11. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med. 2014;370(25):2418-2425.
12. Clinical Sequencing Exploratory Research program. https://cser-consortium.org (accessed July 1, 2015).
13. Bainbridge MN, Wang M, Wu Y, et al. Targeted enrichment beyond the consensus coding DNA sequence exome reveals exons with higher variant densities. Genome Biol. 2011;12(7):R68.
14. Reid JG, Carroll A, Veeraraghavan N, et al. Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis pipeline. BMC Bioinformatics. 2014;15:30.
15. COSMIC. catalogue of somatic mutations in cancer. http://cancer.sanger.ac.uk/cosmic (accessed April 1, 2015).
16. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(Database issue):D805-D811.
17. Kanchi KL, Johnson KJ, Lu C, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun. 2014;5:3156.
18. Robinson JT, Thorvaldsdóttir H, WincklerW, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-26.
19. Gajjar A, Bowers DC, KarajannisMA, Leary S, Witt H, Gottardo NG. Pediatric brain tumors: Innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol. 2015;33(27):2986-2998.
20. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45(3):279-284.
21. Sausen M, Leary RJ, Jones S, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2013;45(1):12-17.
22. Zhou S, Hertel PM, FinegoldMJ, et al. Hepatocellular carcinoma associated with tight-junction protein 2 deficiency. Hepatology. 2015;62(6):1914-1916. doi:10.1002/hep.27872.
23. Astuti D, Morris MR, Cooper WN, et al. Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nat Genet. 2012;44(3):277-284.
24. Green RC, Berg JS, GrodyWW, et al; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565-574.
25. Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014;32(19):2001-2009.
26. Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol. 2015;33(9):975-977.
27. Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012; 488(7409):106-110.
28. Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012;488(7409):43-48.
29. Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882-892.
30. Schneppenheim R, Frühwald MC, Gesk S, et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet. 2010;86(2):279-284.
31. Capasso M, Devoto M, Hou C, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009;41(6): 718-723.
32. Brooks GA, Stopfer JE, Erlichman J, Davidson R, Nathanson KL, Domchek SM. Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic. Cancer Biol Ther. 2006;5(9):1098-1102.
33. Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015; 7(283):283ra53.